权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia

阴部神经调节治疗尿失禁和大便失禁以及括约肌协同失调

基本信息

批准号：
10593689
负责人：
KARL B THOR
金额：
$ 5万
依托单位：
DIGNIFY THERAPEUTICS, LLC
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-30 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10593689
关键词：
Action Potentials Acute Adult Diapers Anal canal Animal Model Animals Ataxia Bilateral Bladder Bladder Control Canis familiaris Caregivers Catheterization Catheters Characteristics Chronic Collagen Colon Complex Conscious Consumption Contracts Deposition Devices Distal Effectiveness Electric Stimulation Electrodes Ensure Extravasation Family suidae Fatigue Fecal Impaction Fecal Incontinence Feces Felis catus Fiber Frequencies Functional disorder Histology Histopathology Hour Human Hypertrophy Implant Incontinence Individual Infection Intestines Investigation Ipsilateral Kidney Failure Lead Life Measures Mediating Medical Device Miniature Swine Monitor Muscle Fibers Nerve Operative Surgical Procedures Patients Persons Pharmaceutical Preparations Phase Physiologic pulse Physiological Preparation Recovery Resistance Safety Skin Small Business Innovation Research Grant Small Business Technology Transfer Research Source Sphincter Spinal Spinal Injuries Spinal cord injury Stigmatization Stimulus Striated Muscles Testing Therapeutic Therapeutic Uses Time Urethra Urethral sphincter Urinary Incontinence Urinary Retention Urinary tract infection Urination Urine Ventral Roots Walking Weight Width awake behavioral study clinically relevant digital experience implantation muscle hypertrophy neuroregulation phase 1 study preclinical development preclinical study pressure prevent programs remote control restoration safety study safety testing social sphincter ani muscle structure standard of care translational study urinary

项目摘要

SUMMARY / ABSTRACT Spinal cord injury (SCI) frequently produces severe, life-long bladder and bowel dysfunction that results in urinary (UI) and fecal incontinence (FI), as well as sphincter dyssynergia that results in urinary retention and fecal impaction. Current standard of care for incontinence consists of modestly effective drugs, complicated surgery, or adult diapers. Bladder and bowel voiding require multiple-times-daily catheterization of the bladder and regular digital extraction of feces for most SCI individuals. Diapers are odiferous, catheters induce frequent urinary tract infections, and digital bowel programs are time-consuming and stigmatizing for the individual and/or their caregiver. For most people with SCI, bladder and bowel dysfunction impacts their professional and social lives more than their inability to walk. Our Phase 1 STTR application, in anesthetized preparations, determined electrical pulse characteristics (e.g. 3T, 100 usec, 10-30 Hz), which when applied to the pudendal (PUD) nerve, stimulated efferent and afferent fibers to produce, respectively, sustained contractions (>1 hour) of the urethral and anal sphincters and inhibition of bladder activity with increased bladder capacity. Bladder leak point pressures were also markedly increased. These physiological effects should significantly reduce UI and FI when replicated in patients. In addition, the same electrodes and stimulator that were used to stimulate the PUD nerve were also able to block the PUD nerve by switching from low frequency to kHz high frequency (constant duty cycle) pulses that prevented sphincter contractions. In Aim 1 of this Phase 2 SBIR application, chronic SCI preparations are first tested to confirm that they respond to the above pulse characteristics similarly to our Phase 1 study in spinal intact studies. For Aim 2, a translational study is performed in which an implantable pulse generator (IPG), is interfaced with electrodes placed bilaterally on the pudendal nerves of chronic SCI preparations for 2 months. During this time, the IPG is used to stimulate the PUD nerve when “Storage” of urine and feces is desired and then switched to block the PUD nerve when “Voiding” of urine and feces is desired. The IPG uses a remote control to switch between Storage Mode and Voiding Mode. Effectiveness in controlling UI and FI episodes is assessed by comparing the number and volume/weight of episodes on test days, with versus without, activation of Storage Mode. Effectiveness for controlling sphincter dyssynergia is assessed by measuring drug-induced voiding efficiency and subjective ratings of Credé difficulty on test days, with versus without, activation of Voiding Mode. At the end of the study sphincters are evaluated for signs of sphincter muscle hypertrophy and increases in fatigue- resistant muscle fibers. Finally, in preparation for FDA discussions, we will assess different preparations in consideration of GLP safety studies.

摘要/摘要